Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Genzyme Corporation v. Impax Laboratories, Inc.
Case Number:
1:09-cv-00653
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
September 05, 2012
Genzyme, Impax Bury Hatchet Over Kidney Disease Drugs
Impax Laboratories Inc. on Tuesday settled patent infringement claims brought by Sanofi-Aventis SA subsidiary Genzyme Corp. over plans to make generic versions of two Genzyme kidney disease treatments, reaching a deal that will give Impax licensing rights in 2014.
-
September 03, 2009
Endo Looks To Join Genzyme-Impax Renagel Battle
Endo Pharmaceuticals Inc. has asked a court for permission to intervene in Genzyme Corp.'s Renagel patent infringement case against Impax Laboratories Inc., arguing that Impax challenged a second patent's validity solely in a bid to force first-filer Endo to forfeit its exclusivity period.